IR contact detailsRoman Akbar-HaaseDirector Investor Relations and Business Developmente: ir@moonlaketx.com Upcoming events Jun 22 2026 from 8:00 AM to 9:30 AM EDT Investor Day Click here for webcast Jul 14 - Jul 15 2026 Leerink I&I and Metabolism Therapeutics Forum, Boston, MA Jul 28 - Jul 29 2026 BTIG Annual Biotechnology Conference, Virtual View All Events View All Events + Corporate presentations MoonLake Investor Day (Jun 2026) MoonLake Investor Day (Feb 2026) Clinical Data Update (Nov 2025) View All Presentations View All Presentations + Latest press releases Jun 21 2026 MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026 May 10 2026 MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results Mar 28 2026 MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting View All News View All Press Releases +
Jun 21 2026 MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
May 10 2026 MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
Mar 28 2026 MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting